Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.

NCT02278588 is registered in ClinicalTrials.gov with State University of New York at Buffalo as lead sponsor.

NCT NCT02278588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02278588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.
Lead sponsor
State University of New York at Buffalo
Phase
Observational
Overall status
Completed
Start date
November 30, 2014
Completion date
December 31, 2017
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease